Chronic Obstructive Pulmonary Diseases Clinical Trial
— RESCUEOfficial title:
RESCUE-COPD 1 Randomised Trial of E-Health Platform Supported Care vs Usual Care After Exacerbation of COPD
There are currently 900,000 people in the UK with a diagnosis of Chronic Obstructive
Pulmonary Disease (COPD), The disease is progressive and often causes disabling symptoms
such as chronic cough, breathlessness and reduced tolerance to exercise. National Institute
for Health and Care Excellence (NICE) recommends that patients with COPD have a self
management plan (SMP). The utilisation of SMP's has been shown to reduce healthcare
utilisation, improve quality of life, and reduces the need for hospitalisation. Currently
SMP's are delivered to patient in a paper format, myCOPD is a web based self management
system which has been developed by Healthcare professional and patients encompasses the
principles of Self management and offers a viable solution to a national recommendation.
The study will compare paper self management plans against the online version myCOPD. The
study aims to recruit 60 patients with a diagnosis of COPD during their admission to
hospital for an exacerbation or flare up of their COPD. Patients will be given an
information sheet during their admission and prior to leaving hospital be asked if they wish
to participate in the study. Patients will participate in the study for no less than two
months and a maximum of three months. 30 patients will receive written self management and
30 will receive online self management. There will be a total of 4 visits for the duration
of the study.
The screening visits will comprise of written or verbal consent, Demographics, Medical,
exacerbation and healthcare utilisation history, Quality of Life questionnaires, inhaler
technique assessment and delivery of either a written self management plan. The telephone
visits will comprise of verbal consent and completion of the COPD Assessment Test. The End
of Study visit will comprise of verbal consent, Demographics, Medical, exacerbation and
healthcare utilisation history, Quality of Life questionnaires and assessment of inhaler
technique.
Status | Completed |
Enrollment | 40 |
Est. completion date | March 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 45 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Subjects able to complete all study procedures and give written informed consent. 2. A diagnosis of COPD defined as per the NICE COPD guidelines 3. Male or female volunteers aged 45+ admitted to hospital or the ambulatory care service with a primary diagnosis of acute exacerbation of COPD 4. Patients who are taking inhaled therapies for COPD 5. Current or ex-smokers with a pack year history of more than 10 years 6. Access to the internet and ability to operate web platform and or use written action plan Exclusion Criteria: 1. Patients who have any another respiratory disease as their main complaint such as asthma, bronchiectasis, lung cancer, tuberculosis or any other significant respiratory disease. 2. Patients unable to read or use an Internet enabled device. 3. Patients with any uncontrolled medical condition which in the view of the principle investigator or their team would confound the impact of a COPD directed support tool. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United Kingdom | Portsmouth Hospital NHS Trust | Portsmouth | Hampshire |
Lead Sponsor | Collaborator |
---|---|
my mhealth Ltd | Portsmouth Hospitals NHS Trust |
United Kingdom,
Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008 Sep;63(9):831-8. doi: 10.1136/thx.2007.086041. Review. — View Citation
Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupré A, Bégin R, Renzi P, Nault D, Borycki E, Schwartzman K, Singh R, Collet JP; Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santé du Québec. Reduction of ho — View Citation
Jones PW, Adamek L, Nadeau G, Banik N. Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. Eur Respir J. 2013 Sep;42(3):647-54. doi: 10.1183/09031936.00125612. Epub 2012 Dec 20. — View Citation
Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009 Sep;34(3):648-54. doi: 10.1183/09031936.00102509. — View Citation
Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7. — View Citation
Rice KL, Dewan N, Bloomfield HE, Grill J, Schult TM, Nelson DB, Kumari S, Thomas M, Geist LJ, Beaner C, Caldwell M, Niewoehner DE. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2010 Oct 1;182(7):890-6. doi: 10.1164/rccm.200910-1579OC. Epub 2010 Jan 14. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | COPD Assessment Test (CAT) | This is a validated symptom scoring system used in COPD studies9 The CAT questionnaire contains eight questions and provides a reliable measure of the impact of COPD on health status. Patients read the two statements for each item, which describe the best and worst scenario, (e.g I never cough - I cough all the time), and decide where on the scale of 0-5 they fit. The maximum score is out of 40. The higher the CAT score the greater the impact of symptoms on their health status. Experts involved in the development of CAT suggest that any change of 2 or more in the patient's final score may indicate a clinically significant change. CAT will be recorded at the start prior to any intervention at visit one and 3 months post intervention at visit 4 | 3 months | No |
Primary | Inhaler technique | As different inhaled medication devices require different techniques, each participant's inhaler technique will be assessed according to manufactures guidelines for each device and critical errors recorded. Their technique will be video recorded at visit one and visit two. Any changes to devices during the study will be recorded prior to starting any new treatment. Each participant's technique will be evaluated and the number of critical errors recorded for each device and a composite . Each device will have its own critical error list we have created based on manufactures guidelines. Participants technique will be videoed and assessed using a critical error list for each device by a Health care Professional. This assessment will take place at visit one prior to intervention and 3 months post intervention at visit 4. The difference in the number of errors for each device pre and post intervention will then be recorded. | 3 months | No |
Secondary | St Georges Respiratory Questionnaire (SGRQ) | The SGRQ questionnaire has 50 items with 76 weighted responses. It has good discriminative and evaluative properties and is responsive to therapeutic trials. It was developed and validated in both asthma and COPD and designed to measure the health impairment of patients with respiratory disease. We will be assessed at visit one prior to intervention and 3 months post intervention | 3 months | No |
Secondary | modified MRC | The mMRC dyspnoea scale comprises five statements that describe almost the entire range of respiratory disability from none (Grade 0) to almost complete incapacity (Grade 4). It can be self-administered by asking subjects to choose a phrase that best describes their degree of breathlessness associated with activity. This will be assessed prior to and three months post intervention | 3 months | No |
Secondary | Hospital Anxiety and Depression Score (HAD) | This clinical scale was developed in 1983 and is in common use in clinical and trial settings. It consists of 7 questions scored form 0-3 to create a score out of 21. It is easily administered and has been well validated for the assessment of patients with COPD. This will be assessed prior to and three months after intervention | 3 months | No |
Secondary | Patient Activation Measure (PAM) | PAM is a tool used for measuring the level of patient engagement in their healthcare. It was designed to assess an individual's knowledge, skill and confidence for self-management. PAM is a 13-item scale that asks people about their beliefs, knowledge and confidence for engaging in a wide range of health behaviors and then assigns an activation score based on their responses to the 13-item scale. This will be assessed prior to and three months post intervention. | 3 months | No |
Secondary | Work Productivity Activity Impairment (WPAI) | The Work Productivity and Activity Impairment (WPAI) questionnaire is a well validated instrument to measure impairments in work and activities. The 6 questions relate to work absenteeism (hours missed work) Work presenteeism (impairment whilst working) and work productivity lost due to a health condition. This will be assessed prior to and three months post intervention | 3 months | No |
Secondary | Veterans Specific Activity Questionnaire (VSAQ) | The VSAQ is validated Self administered questionnaire developed to estimate exercise capacity for the development of exercise prescription. The VSAQ consists of physical activities listed in progressive order according to their energy demand estimated by metabolic equivalents (METs). One MET is equal to resting oxygen consumption 3.5 ml/kg/min. Therefore, numbers of METs express the energy cost of physical activities as a multiple of the resting metabolic rate. This will be assessed prior to and three months post intervention | 3 months | No |
Secondary | Exacerbation History | COPD exacerbation data will be collecting from their primary prescriber on their exacerbation history. The numbers of COPD exacerbations requiring oral antibiotics and/or oral steroids by the participants one year prior to starting the study will be recorded at visit one. If the participant has any exacerbations requiring oral antibiotics and/or steroids required during the period of the study this will be recorded at visit four. | 3 months | No |
Secondary | Admission and readmission data | Admission and readmission data will be collected at visit 1 and visit 4 and verified by the GP patient records or other source data. | 3 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01785537 -
The Efficacy and Safety of Electronic Cigarettes: a 5-year Follow-up Study
|
N/A | |
Completed |
NCT02706613 -
Comparing Online Pulmonary Rehabilitation 'myPR' Versus Conventional Pulmonary Rehabilitation for Patients With COPD
|
N/A | |
Completed |
NCT01463644 -
Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis
|
Phase 3 | |
Recruiting |
NCT01360931 -
The Roles of Neutrophil Elastase in Lung Cancer
|
N/A | |
Completed |
NCT03461328 -
Effect of Magnesium Sulphate Infusion on Lung Mechanics and Oxygenation in COPD Patients Undergoing Total Laryngeal
|
Phase 4 | |
Terminated |
NCT02707770 -
The Role of Ambulatory Oxygen in Improving the Effectiveness of Pulmonary Rehabilitation for COPD Patients
|
N/A |